# Semaglutide and Motivation

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-31

Canonical page: https://glpwatchdog.org/research/semaglutide-and-motivation

> Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.

## Key points

- Effort sensitivity fell (β = −1.737, p=0.03); probability sensitivity did not (p=0.51).
- A placebo or engagement effect should move both parameters. One moved.
- Secondary analysis of a trial that missed its primary endpoint.
- The parent trial found no change in depressive symptoms, so this is not an antidepressant effect.

In a randomized trial, semaglutide reduced how heavily people with major depressive disorder discounted effort, making them more willing to work for a reward.[1] The same trial [missed its primary cognitive endpoint](https://glpwatchdog.org/research/semaglutide-depression-cognition-trial), which is a reason for caution. What makes this particular secondary finding more interesting than most is *what it did not move*.

## What was measured

Effort-based decision-making tasks ask people to choose between an easy task for a small reward and a harder one for a larger reward. Computational modeling then separates two things that look similar from the outside: how much someone dislikes effort, and how much they discount an uncertain payoff.

*Two parameters from the same decision task.*

| Parameter | Effect of semaglutide | p |
| --- | --- | --- |
| Sensitivity to **effort** | β = −1.737 (reduced) | 0.03 |
| Sensitivity to **probability** | β = −0.776 | 0.51 |

The authors describe the result as a reduction in the perceived cost of effort relative to the monetary reward.[1] Things felt less expensive to do.

## Why the null in the second row matters

> A general lift in mood, engagement or expectation should move both parameters. This moved one.

That dissociation is the strongest thing about the finding. If participants had simply felt better, or tried harder because they believed they were on an active drug, you would expect their whole approach to the task to shift. Instead one specific parameter moved and a closely related one did not.

It is not proof of a mechanism, but it is the kind of specificity that separates a plausible signal from the general warm glow that contaminates most secondary psychiatric outcomes.

## The caution that has to travel with it

This is a secondary analysis of a trial whose primary endpoint failed. Executive function, the outcome the study was built and powered to test, showed no effect, with a confidence interval spanning zero. When a primary fails and secondaries succeed, the trial has answered its question with a no, and the secondaries are suggestions for the next study.

The parent trial also found **no effect on depressive symptom severity**. Mood did not change, so whatever this is, it is not an antidepressant effect showing up on a motivation measure.

> **There is an obvious alternative explanation.** Anhedonia and low motivation in depression are strongly linked to metabolic health, sleep and physical capacity. A drug that reduces weight substantially may make effort cheaper in a physical sense: less mass to move, better sleep, less pain. That would be a real benefit arriving by an entirely ordinary route rather than through reward circuitry.

## Why it is being taken seriously anyway

The authors note implications for neuropsychiatric disorders characterized by reward dysfunction, a group that includes depression, schizophrenia and substance use disorders. This connects to a body of work we have covered: a randomized trial in [alcohol use disorder](https://glpwatchdog.org/research/semaglutide-for-alcohol-use-disorder) that found a real effect, [cohort data](https://glpwatchdog.org/research/glp1s-and-worsening-mental-illness) showing lower rates of worsening substance use, and health records in which people with [opioid use disorder who had a GLP-1 prescription overdosed less often](https://glpwatchdog.org/research/glp1-and-opioid-use-disorder).

A drug that changes how costly effort feels, and that separately cut drinks per drinking day and craving in a 48-person randomized trial,[2] is doing something to reward processing. What that something is, and whether it helps anyone in a way they would notice, is not settled by a task in a laboratory.

## Frequently asked questions

### Does semaglutide improve motivation?

In a randomized trial in major depressive disorder it reduced how heavily people discounted effort, meaning the perceived cost of doing something relative to the reward. It is a secondary analysis of a trial that missed its primary cognitive endpoint.

### Why does it matter that probability sensitivity did not change?

Because a general lift in mood, engagement or expectation would be expected to shift the whole approach to the task. One parameter moving while a closely related one stayed still is harder to explain as a placebo or expectation effect.

### Did it treat the depression?

No. The parent trial found no effect on depressive symptom severity. Whatever this finding represents, it is not an antidepressant effect appearing on a motivation measure.

### Could the weight loss explain it?

Plausibly. Motivation and anhedonia are tied to metabolic health, sleep and physical capacity, so a drug that removes substantial weight may make effort cheaper in a physical sense. That would be a real benefit by an ordinary route rather than through reward circuitry.

### Should anyone take it for motivation?

No. This is a laboratory task in a small secondary analysis after a failed primary endpoint, with no approved indication anywhere near it.

## References

1. Gill H, Badulescu S, Shah H, et al. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 42054055. https://pubmed.ncbi.nlm.nih.gov/42054055/
2. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 39937469. DOI: 10.1001/jamapsychiatry.2024.4789. https://pubmed.ncbi.nlm.nih.gov/39937469/

---

Cite as: GLP Watchdog, Nora Bissett, "Semaglutide and Motivation", published 2026-08-20, updated 2026-10-31. https://glpwatchdog.org/research/semaglutide-and-motivation

Canonical HTML page: https://glpwatchdog.org/research/semaglutide-and-motivation

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
